Searched for: author:"Nooijen, I.H.G."
(1 - 5 of 5)
document
van de Steeg, E. (author), Schuren, F.H.J. (author), Nooijen, I.H.G. (author), Erpelinck, S. (author), Scott Obach, R. (author), Vaes, W.H.J. (author)
Gut microbiota plays a major role in metabolizing xenobiotics into active, inactive or toxic metabolites, thereby influencing pharmacokinetics, efficacy and toxicity profiles of prescribed drugs, which is currently being underexplored.
public lecture 2019
document
Amirabadi, H. Eslami (author), Wierenga, E. (author), Stevens, L.J. (author), Donkers, J. (author), Donkers, T. (author), Ingenhut, B.L.J. (author), Usta, B. (author), Pieters, L. (author), Gröllers, M. (author), Nooijen, I.H.G. (author), Erpelinck, S.L.A. (author), Schuren, F. (author), Masereeuw, R. (author), van de Steeg, E. (author)
The majority of screening and predictive models do not reflect the physiology of the human intestinal tract since they show major limitations to include the processes that determine the oral bioavailability1,2. A major drawback of current intestinal models is the use of single cell lines and the static environment, which is in contrast with the...
public lecture 2019
document
van de Steeg, E. (author), Schuren, F.H.J. (author), Obach, R.S. (author), van Woudenbergh, C. (author), Walker, G.S. (author), Heerikhuisen, M. (author), Nooijen, I.H.G. (author), Vaes, W.H.J. (author)
Colon microbiota-based drug metabolism has received little attention thus far in the process of drug development, whereas the role of gut microbiota in clinical safety and efficacy of drugs has become more clear. Many of these studies have been performed using animal studies, but the translational value of these data with respect to drug...
article 2018
document
van de Steeg, E. (author), Venhorst, J. (author), Jansen, H.T. (author), Nooijen, I.H.G. (author), Degroot, J. (author), Wortelboer, H.M. (author), Vlaming, M.L.H. (author)
Human organic anion-transporting polypeptide 1B1 (OATP1B1) and OATP1B3 are important hepatic uptake transporters. Early assessment of OATP1B1/1B3-mediated drug-drug interactions (DDIs) is therefore important for successful drug development. A promising approach for early screening and prediction of DDIs is computational modeling. In this study...
article 2015
document
van de Steeg, E. (author), Greupink, R. (author), Schreurs, M. (author), Nooijen, I.H.G. (author), Verhoeck, K.C.M. (author), Hanemaaijer, R. (author), Ripken, D. (author), Monshouwer, M. (author), Vlaming, M.L.H. (author), DeGroot, J. (author), Verwei, M. (author), Russel, F.G.M. (author), Huisman, M.T. (author), Wortelboer, H.M. (author)
Organic anion-transporting polypeptide 1B1 (OATP1B1) is an important hepatic uptake transporter, of which the polymorphic variant OATP1B1*15 (Asn130Asp and Val174Ala) has been associated with decreased transport activity. Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic. The aim of...
article 2013
Searched for: author:"Nooijen, I.H.G."
(1 - 5 of 5)